Celgene commits $1.9B to Acceleron

Celgene has agreed to option three development programs at Acceleron and collaborate on the development of its lead bone formation protein in two deals that could be worth upwards of $1.9 billion. Celgene is paying Acceleron $50 million up front and a $5 million equity payment and up to $510 million in milestones for ACE-011--which is in an early-stage trial. On top of that, Celgene will take a minimum $7 million equity stake in Acceleron if it goes public. And there's an additional $1.3 billion in payments for the options on discovery stage programs targeting cancer and cancer-related bone loss. A mid-stage trial of ACE-011 is expected to get underway later this year.

"This collaboration is an excellent strategic fit for Acceleron and the ACE-011 program. Celgene is one of the most successful biotech companies in the world and is the leader in the field of blood cancers, including multiple myeloma, an indication where ACE-011 has great potential," said John Knopf, Ph.D., CEO of Acceleron. Knopf signaled an approaching deal to FierceBiotech last fall, saying it expected to get a collaboration agreement inked in the first quarter. The biotech company delivered right on schedule.

- check out this release on the deal
- read the report from MassHighTech

Related Articles:
Celgene goes global with $2.9B Pharmion buyout. Report
Revlimid fuels Celgene sales rocket. Report
The race is on for muscle-enhancing therapies. Report
Acceleron takes a lesson from the giant Belgian blue. Report
Acceleron garners $30M in venture capital. Report

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.